Guideline‑Directed Management of Stage 3A Chronic Kidney Disease (eGFR 45–59 mL/min/1.73 m²)

Diagnosis and Risk Stratification

Stage 3A CKD is defined by an estimated GFR of 45–59 mL/min/1.73 m², representing roughly a 50 % reduction in normal kidney filtration compared with young healthy adults. 1
Urine albumin‑to‑creatinine ratio (UACR) should be measured immediately because it is the single most important test for assessing kidney disease risk and guiding all subsequent treatment decisions. 2
Approximately 23 % of individuals with eGFR 45–59 mL/min/1.73 m² are misclassified when only creatinine‑based equations are used; cystatin C measurement can confirm or refute the CKD diagnosis. 1
Serum creatinine alone substantially underestimates kidney dysfunction, especially in older adults, women, and persons with low muscle mass. 1

Target blood pressure < 120/80 mmHg (if tolerated) to slow CKD progression. 2

If UACR ≥ 30 mg/g, initiate an ACE‑inhibitor or ARB at the highest tolerated dose to reduce proteinuria and protect kidney function. 2

SGLT2‑inhibitor therapy (empagliflozin, dapagliflozin, canagliflozin) is recommended for patients with diabetes or significant albuminuria, as these agents lower CKD progression and cardiovascular events even when eGFR > 20 mL/min/1.73 m². [4][2]
Statin therapy should be started for cardiovascular risk reduction in all Stage 3A CKD patients. 2

Repeat eGFR and UACR every 3–6 months in Stage 3A CKD to track disease trajectory. 2

Avoid nephrotoxic medications, including non‑steroidal anti‑inflammatory drugs (NSAIDs), certain antibiotics, and iodinated contrast agents, whenever possible. 5